SI-BONE Inc

SI-BONE reported Q1 2026 revenue of $52.6m (+11.2%) and adjusted EBITDA of $2.5m, a 440% improvement year-over-year. The active physician base rose 17.3% to a record 1,650 doctors, and procedure volume in the US grew by 8%. The company raised its full-year revenue guidance to $230–233m and expects a gross margin of around 79%; cash stands at $144.7m. Despite progress, a net loss of $4.3m remains, and management highlights risks related to market penetration, reimbursements, and production capacity. » More on de.investing.com

Si-Bone reported Q1 2026 earnings per share of -$0.10, beating the consensus expectation of -$0.19. Revenue was $52.6 million (+11.2% y/y), missing the estimate of $52.85 million only slightly. Gross margin remained high at 79.8%, adjusted EBITDA rose to $2.5 million (+440%), and the stock climbed 1.79% in after-hours trading. Management raised the full-year guidance and expects accelerated revenue growth. » More on de.investing.com

Si-Bone announced at the TD Cowen Health Care Conference that it is shifting from a single-product focus to a provider of comprehensive solutions for damaged bone, driven by partnerships and new product launches. The partnership with Smith & Nephew is intended to drive growth in the trauma market, and the launch of INTRA Ti targets the interventional segment. Si-Bone aims for revenue to grow 1.2–1.7 times faster than operating expenses and expects gross margins of 78–79%. Financing and reimbursement improvements (including NTAP for TNT and a new APC code for Granite) are expected to support growth; the company plans to apply for approval of a new Breakthrough Device in Q3 2026 and to commercialize it in late 2026/early 2027. » More on de.investing.com